Immunitybio is trading 10.05% higher at $10.21, with no clear company-specific announcement explaining the October 2 move. - The company is scheduled to present at the Thoracic Rare Cancer Symposium in Ottawa; the listing alone does not establish a cause. - The S&P 500, Nasdaq Composite and Dow Jones are also higher, though a direct link to Immunitybio’s rise has not been established.